
CervoMed Investor Relations Material
Latest events

Status Update
CervoMed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CervoMed Inc
Access all reports
CervoMed Inc. is a biotechnology company specializing in the development and commercialization of treatments for age-related neurologic disorders. The company’s key focus is on addressing synaptic dysfunction, a critical factor in neurodegenerative diseases. Its lead product candidate, neflamapimod, is an orally administered small molecule designed to treat conditions such as dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia by reversing synaptic dysfunction. CervoMed also has additional programs targeting central nervous system disorders in earlier stages of development. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for CervoMed Inc


Corporate Presentation
CervoMed Inc


Corporate Presentation
CervoMed Inc
Latest articles
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
Ticker symbol
CRVO
Country
🇺🇸 United States